While substantial tax cuts on key cancer drugs signify a noteworthy effort to alleviate financial burdens, the journey toward accessible and equitable healthcare in India is fraught with challenges that extend beyond mere pricing. The complexity of cancer treatment necessitates not only financial considerations but also addressing critical non-financial barriers that impede patient access to advanced cancer care.
The Necessity of Sophisticated Biomarker Testing
Advanced cancer therapies such as Trastuzumab Deruxtecan, Osimertinib, and Durvalumab are often contingent upon precise biomarker testing to ensure they are administered to the right patients—those who exhibit specific molecular characteristics. For example:
- HER2 Testing is essential for Trastuzumab Deruxtecan, requiring robust immunohistochemistry (IHC) methodologies and possibly additional confirmatory techniques like in-situ hybridization (ISH).
- EGFR Testing is mandatory for Osimertinib, involving targeted molecular testing to identify specific gene mutations through advanced methods such as Next-Generation Sequencing (NGS) or PCR-based assays.
- PD-L1 Testing is relevant for Durvalumab’s efficacy in certain applications, necessitating further IHC assessments.
However, the means to conduct these sophisticated tests are fraught with complications. Infrastructure limitations and a shortage of trained professionals, such as pathologists and molecular biologists, hinder widespread testing. As a result, even patients eligible for these drugs may face delays or inability to confirm their candidacy for these advanced therapies due to inadequate testing facilities,.
Infrastructure Limitations and Cost Constraints
Access to biomarker testing is not uniformly available across the country. Advanced diagnostic services are primarily concentrated in major urban centers and tertiary care hospitals, leaving patients in Tier 2 and Tier 3 cities and rural areas potentially without timely access to necessary tests. This urban-rural divide is exacerbated by infrastructural deficiencies, such as:
- Limited availability of advanced testing facilities, resulting in long travel times for patients who need tests that are only offered at select urban hospitals.
- High costs associated with molecular testing, which can further exclude low-income patients who might not afford the tests even if they are available nearby.
- Long turnaround times for results, often exceeding ideal timeframes, which can delay critical treatment decisions for patients.
The Urban-Rural Divide in Specialized Oncology Care
The disparity in access to oncology care between urban and rural areas poses a significant hurdle. Urban areas typically host a concentration of specialized oncology services, while rural regions often lack essential resources and trained professionals. Consequently, patients from these underserved regions face compounded barriers, including:
- Travel burdens and associated costs: Patients may need to travel long distances for consultations and treatments, increasing their financial strain.
- Inconsistent drug availability: Specialized treatments may also suffer from distribution challenges, making it difficult for rural healthcare facilities to procure advanced cancer drugs regularly.
The potential lack of consistent supply chains can jeopardize continuity of care and leave remote patients reliant on treatments that are simply unavailable,.
Cost Reduction Is Not Enough
While financial reductions in cancer drug prices represent a significant step toward improving access to care, these measures address only a fraction of the problems facing patients. The intricate interplay of infrastructure limitations, geographical disparities, and the need for timely biomarker testing is crucial in determining whether patients can genuinely benefit from the newly affordable treatments.
Policymakers must recognize that effective interventions require a multi-faceted approach, involving not only pricing strategies but also strengthening healthcare infrastructure, enhancing diagnostic capabilities, and ensuring equitable distribution of advanced cancer therapies throughout the country. Without addressing these hidden hurdles, the potential of pricing reforms may remain unrealized for countless patients in need of critical oncology care.
–(Dr) Rithvisha Kiran
